In TP53‐mutant HBCx‐14‐bearing mice, while the DMSO or PFT‐α alone treatment groups showed continuous tumor growth over a period of 5 weeks, the CDDP‐treated group showed significant tumor shrinkage (Fig 6H). The gene discussed is TP53; the disease is neoplasm.